Search results for Cil001 Tinnitus Drug

Cilcare Announces US Clinical Trial for Tinnitus Drug, Expands Research Capacity

The company plans a clinical trial for its CIL001 drug candidate at Massachusetts General Hospital and will triple preclinical capacity through its partnership with CBSET.

Lenire Tinnitus Treatment Device Available in Canada

The bimodal neuromodulation device is now available through select hearing care clinics across five provinces.

Tinnitus App Using ACT and CBT Principles to Enter US Market

European-developed Freequency, backed by key psychology experts, launches US pilot program at AAA 2026.

Tinnigone® Highlights Rising Interest in Nutritional Approaches to Ear Ringing and Hearing Wellness

Search trends and growing prevalence highlight increased public attention toward auditory health WEST PALM BEACH, Fal., May 2, 2026 /PRNewswire-PRWeb/ -- Search interest in ear rin...

<![CDATA[FDA Approves Otarmeni Gene Therapy for OTOF-Related Hearing Loss]]>

SSRIs May Trigger Tinnitus

A new study identifies a specific serotonin circuit that triggers the auditory system, explaining why SSRIs can worsen tinnitus and offering a new target for treatment.

The Serotonin Circuit That Makes Tinnitus Louder

Serotonin lifts moods. Sometimes it also makes ears ring harder. In a new paper out in PNAS, researchers at Oregon Health & Science University and Anhui University in China des...

FDA approves Regeneron’s hearing loss gene therapy

Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to...

First Gene Therapy for Genetic Hearing Loss, Otarmeni, Gains FDA Approval

MONDAY, April 27, 2026 — In a historic leap for medical science, the U.S. Food and Drug Administration (FDA) has greenlit the first-ever gene therapy to treat a rare form of inheri...

EMA Accepts Otarmeni Gene Therapy for OTOF-Related Hearing Loss for Review

If approved, Regeneron's Otarmeni will be the first gene therapy for OTOF-related hearing loss in the European Union.

Gene Cure For Inherited Deafness Effective, Long Lasting, Clinical Trial Finds

THURSDAY, April 23, 2026 — A new gene therapy to treat inherited deafness produces a lasting cure, a new international study has found. The treatment, which targets the OTOF gene,...

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cispla...

PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to

Neurotone AI Surpasses 1,000 Clinic Partners as Aural Rehabilitation Becomes a Standard of Care

Lace and Tinnitus Pro adoption expands worldwide as hearing care moves beyond devices alone. GAINESVILLE, Fla., April 16, 2026 /PRNewswire-PRWeb/ -- Neurotone AI today announced th...

Tinnitus May Be Linked to a Crucial Brain Chemical

This points to potential treatments.ScienceAlert stories are written, fact-checked, and edited by humans, never generated by AI. Don't miss a story, subscribe here.

Sound Wave Innovation from Tohoku University Raises ¥26.5 Billion in Series C for Clinical Trials of Dementia Treatment...

Sound Wave Innovation, a company developing ultrasound-based dementia treatment devices, announced on the 18th that it has raised approximately ¥26.5 billion in a Series C round ai...

Relentless tinnitus drove Amber crazy. No treatments worked... until a routine appointment led to this simple fix that s...

For Amber Ford, the worst part of the menopause was the relentless ringing in her ears - tinnitus. She lived with a constant buzzing for six months, alongside neck pain, jaw tensio...

Regeneron Gets Landmark FDA Approval for First Gene Therapy for Hearing Loss

Regeneron Pharmaceuticals’ Otarmeni is now approved for treating hearing loss from an ultra-rare genetic mutation found in an estimated 50 newborns per year. While Regeneron will o...

Advanced Bionics Announces Research Collaboration with Spiral Therapeutics

The partnership aims to explore the integration of novel drug-delivery methods with future cochlear implant technology.

Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain

Tortugas Neurosciences’ two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led by veterans of Sage Therapeutics, a...

On the Cusp of Completely Implantable Cochlear Implants

With several completely implantable CIs in development, a new device choice for patients with severe-to-profound hearing loss is on the horizon.

FDA Grants Accelerated Approval to Otarmeni Gene Therapy for OTOF-Related Hearing Loss

The adeno-associated virus vector-based gene therapy is indicated for pediatric and adult patients with severe-to-profound hearing loss due to biallelic OTOF gene variants.

Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)

Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clini...

Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody

CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical...

The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentati...

CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinica...